Table 2.
Evaluation of Treatment Efficacy
| Indicators | Fluoxetine (n=37) | Fluoxetine + CBT (n=27) | Fluoxetine + Bupropion (n=34) | Fluoxetine + Bupropion + Brain Stimulation (n=15) | P | |
|---|---|---|---|---|---|---|
| Primary endpoint | 17-HDRS | 9 (4,14) | 8 (4,16) | 9.5 (4,15) | 8 (0,16) | 0.779 |
| Response (17-HDRS score decrease ≥50%), n (%) | 22 (59.5%) | 18 (66.7%) | 22 (64.7%) | 10 (66.7%) | 0.927 | |
| Remission (17-HDRS total score ≤7), n (%) | 16 (43.2%) | 14 (51.9%) | 13 (38.2%) | 8 (53.3%) | 0.658 | |
| Melancholic subscale# | 5 (1,7) | 4 (1,7) | 4.5 (2,8) | 1 (0,8) | 0.692 | |
| HAMD-01 | 1 (0,2) | 1 (0,2) | 1 (0,1) | 0 (0,1) | 0.510 | |
| HAMD-02 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0.937 | |
| HAMD-03 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,2) | 0.906 | |
| HAMD-04 | 1 (0,1) | 1 (0,1) | 0 (0,1) | 0 (0,2) | 0.901 | |
| HAMD-05 | 1 (0,1) | 0 (0,1) | 0.5 (0,1) | 0 (0,1) | 0.874 | |
| HAMD-06 | 0 (0,1) | 0 (0,1) | 1 (0,2) | 0 (0,1) | 0.110 | |
| HAMD-07 | 1 (0,2) | 1 (0,2) | 1 (0,2) | 0 (0,3) | 0.896 | |
| HAMD-08 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0.843 | |
| HAMD-09 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0.189 | |
| HAMD-10 | 1 (0,2) | 1 (0,2) | 1 (0,2) | 1 (0,2) | 0.949 | |
| HAMD-11 | 0 (0,1) | 1 (0,1) | 0.5 (0,1) | 0 (0,1) | 0.790 | |
| HAMD-12 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0.947 | |
| HAMD-13 | 1 (0,1) | 1 (0,1) | 0 (0,1) | 0 (0,2) | 0.660 | |
| HAMD-14 | 0 (0,1) | 0 (0,1) | 0 (0,1) | 0 (0,0) | 0.575 | |
| HAMD-15 | 0 (0,0) | 0 (0,0) | 0 (0,1) | 0 (0,0) | 0.940 | |
| HAMD-16 | 0 (0,0) | 0 (0,0) | 0 (0,0) | 0 (0,0) | 0.891 | |
| HAMD-17 | 0 (0,0) | 0 (0,0) | 0 (0,1) | 0 (0,0) | 0.019 | |
| Secondary endpoint | QIDS-SR | 8 (3,12) | 11 (4,15) | 10 (5,17) | 5 (0,19) | 0.433 |
| QOL-6 | 20.7±2.96 | 20.21±2.17 | 19.56±3.72 | 20.71±3.99 | 0.541 |
Note: #The items for the melancholic subtypes are #1-2-6-7-8-9-12-16.
Abbreviations: CBT, cognitive behavioral therapy; 17-HDRS, 17-item Hamilton Depression Rating Scale; QIDS-SR, Self-Rating version of Quick Inventory of Depressive Symptomatology; QOL-6, Quality of Life 6.